Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 4 versus SERPASIL APRESOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 4 versus SERPASIL APRESOLINE.
METATENSIN #4 vs SERPASIL-APRESOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
None Documented
None Documented
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination